- Allied-Bristol Life Sciences (ABLS) has
licensed a proprietary platform technology from Yale University,
developed in the laboratory of Dr. David Spiegel.
- The proprietary platform, and
associated lead molecules known as Antibody-Recruiting molecules
(ARMs), provide a novel approach for the treatment of cancer.
Allied-Bristol Life Sciences, LLC, a biopharmaceutical
enterprise jointly owned between Allied Minds (LSE: ALM) and
Bristol-Myers Squibb Company (NYSE: BMY), announced that it has
entered into a worldwide licensing agreement with Yale University
for a proprietary platform technology and associated lead molecules
that will be further developed to treat diseases such as prostate
cancer, a leading cause of cancer-related deaths among American
men.
Developed by Professor David A. Spiegel, Ph.D., M.D. and his
team at Yale University, the proprietary synthetic molecules, known
as Antibody Recruiting Molecules (ARMs), work by harnessing the
power of the body’s own immune system to treat cancer. The ARMs do
this by recruiting antibodies already present in the bloodstream
and then leading these antibodies to a specific protein found on
the surface of cancer cells. From there, the antibodies perform
their natural immune function of destroying the diseased cells.
Traditional antibody therapeutics, due to their molecular size
and structure, often must be administered intravenously. They are
costly to manufacture and may elicit undesirable immune reactions
that in some patients reduces their efficacy. The ARMs developed at
Yale offer the promise of less expensive manufacturing and reduced
potential for such unwanted immune reactions.
“We are very excited to begin working with ABLS,” said Dr.
Spiegel. “Our work is at a critical point in its translation, where
the resources and expertise of the ABLS team will make all the
difference in bringing these therapies to patients as quickly as we
can, something that my lab and I are deeply committed to do.”
Dr. Spiegel holds faculty appointments in Yale’s Department of
Chemistry as well as its Department of Pharmacology at the Yale
School of Medicine. He has received numerous awards and honors,
including the American Chemical Society Medical Chemistry Young
Investigator Award, Bristol-Myers Squibb Innovation Award, Novartis
Early Career Award in Organic Chemistry, and the National Institute
of Health’s New Innovator Award. He is the author of more than 30
scientific articles, and his work has been featured by leading
media outlets, including the New York Times, Popular Science, and
Scientific American.
“Dr. Spiegel’s ARM approach presents a differentiated solution
that has strong potential to develop next-generation oncology drugs
with improved safety and efficacy,” said Satish Jindal, Chief
Executive Officer of ABLS. “We are eager to work with David and
Yale on this program. This innovative university technology and
associated lead molecules are at the ideal stage that we are
seeking, where we can bring to bear the drug discovery and
development expertise of ABLS and its partners to accelerate
therapies to the clinic.”
The licensing agreement with Yale is the second in a series of
discovery and development projects that Allied-Bristol Life
Sciences intends to pursue. The license to the technology from Dr.
Spiegel’s lab will be held by a new ABLS subsidiary that was
specifically formed to complete further research and pre-clinical
characterization of a specific set of molecules based on the
technology so that a clinical candidate can be advanced.
For more information about Allied-Bristol Life Sciences, please
visit www.ablifescience.com.
About Allied-Bristol Life SciencesAllied-Bristol Life
Sciences (ABLS) is a jointly owned enterprise between Allied Minds
and Bristol-Myers Squibb Company. Based upon compelling biological
discoveries and insights from scientists at leading U.S. research
institutions, ABLS identifies, sources and de-risks promising,
early-stage therapeutic opportunities, from discovery through
pre-clinical development, in key therapeutic areas, including
fibrosis, cardiovascular diseases, oncology, immunology, virology
and genetically defined diseases. For more information, visit
www.ablifescience.com.
About Yale UniversityYale University, a pre-eminent
global university founded in New Haven, Connecticut in 1701,
consists of three major academic components: Yale College, for
undergraduate liberal arts; the Graduate School of Arts and
Sciences, offering advanced degrees in 73 departments and programs;
and the 13 professional schools. In addition, the campus boasts an
array of centers and programs, libraries, museums, and research
facilities. Yale’s mission to create, preserve, and disseminate
knowledge is manifest in its world-class faculty and staff,
outstanding student body, and dedicated alumni around the world.
For over 300 years, Yale has been committed to developing leaders
in service to society.
About Allied MindsAllied Minds (LSE: ALM) is an
innovative U.S. science and technology development and
commercialization company. Operating since 2006, Allied Minds
forms, funds, manages and builds products and businesses based on
innovative technologies developed at leading U.S. universities and
federal research institutions. Allied Minds serves as a diversified
holding company that supports its businesses and product
development with capital, central management and shared services.
More information about the Boston-based company can be found at
www.alliedminds.com.
About Bristol-Myers SquibbBristol-Myers Squibb is a
global pharmaceutical company whose mission is to discover, develop
and deliver innovative medicines that help patients prevail over
serious diseases. For more information about Bristol-Myers Squibb,
visit www.bms.com, or follow us on Twitter at
http://twitter.com/bmsnews.
Allied Minds Forward-Looking StatementThis press release
contains statements that are or may be forward-looking statements,
including statements that relate to the company’s future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
company’s regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law,
regulatory requirement, the Listing Rules and the Disclosure and
Transparency Rules, neither the company nor any other party intends
to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that the licensing agreement mentioned in this release will lead to
identifying a pre-clinical candidate. Nor is there any
guarantee that if one is identified, it will be successfully
developed for or approved for any of the indications described in
this release. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2014 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150826006218/en/
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660
x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024